Cytokinetics stock jumped 22% on Thursday: what happened?

December 22, 2023 05:13 AM AEDT | By Invezz

Cytokinetics stock jumped 22% on Thursday: what happened? — Image source: Invezz

Buyers are awaiting late-stage study data

The news arrives a couple months after the California-based company was reported exploring its options.

Cytokinetics will publish results of a late-stage trial that tested its aficamten in patients of hypertrophic cardiomyopathy in the coming days.

Both AstraZeneca and Novartis are in a “wait-and-see mode” in the meantime, as per anonymous sources that talked to Dealreporter on Thursday.

If approved, aficamten – the drug that Oppenheimer analyst Justin Kim called a “crown jewel in terms of the pipeline” – will be the first commercial product of Cytokinetics Inc if approved.

Watch here: https://www.youtube.com/embed/e3hf-TD2GvM?feature=oembed

Cytokinetics insider recently sold stock

Note that other strategic buyers have also approached the biotechnology company for a potential deal, as per people familiar with the matter.

Cytokinetics Inc was previously reported working with an investment bank following takeover interest from a Swiss-based company.

In November, the Nasdaq-listed firm reported its financial results for the third quarter that missed Street estimates. Cytokinetics stock is now up close to 65% versus its year-to-date low.

A regulatory filing recently said an insider of the Nasdaq-listed firm has sold $461,875 worth of its stock. Wall Street currently has a consensus “buy” rating on Cytokinetics stock.

Henderson John T Director of Cytokinetics, Incorporated $CYTK just acquired 10.6K shares, growing their position by 33% https://t.co/kOAkDBq4mz
— X-Files Market Investigators (@market_x_files) December 21, 2023

The post Cytokinetics stock jumped 22% on Thursday: what happened? appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.